LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions.

    Cortellini, A / Barrichello, A P C / Alessi, J V / Ricciuti, B / Vaz, V R / Newsom-Davis, T / Evans, J S / Lamberti, G / Pecci, F / Viola, P / D'Alessio, A / Fulgenzi, C A M / Awad, M M / Pinato, D J

    Annals of oncology : official journal of the European Society for Medical Oncology

    2022  Volume 33, Issue 11, Page(s) 1202–1204

    MeSH term(s) Humans ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use
    Chemical Substances pembrolizumab (DPT0O3T46P) ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents, Immunological
    Language English
    Publishing date 2022-08-08
    Publishing country England
    Document type Multicenter Study ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2022.07.1851
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS

    Ricciuti, B / Alessi, J V / Elkrief, A / Wang, X / Cortellini, A / Li, Y Y / Vaz, V R / Gupta, H / Pecci, F / Barrichello, A / Lamberti, G / Nguyen, T / Lindsay, J / Sharma, B / Felt, K / Rodig, S J / Nishino, M / Sholl, L M / Barbie, D A /
    Negrao, M V / Zhang, J / Cherniack, A D / Heymach, J V / Meyerson, M / Ambrogio, C / Jänne, P A / Arbour, K C / Pinato, D J / Skoulidis, F / Schoenfeld, A J / Awad, M M / Luo, J

    Annals of oncology : official journal of the European Society for Medical Oncology

    2022  Volume 33, Issue 10, Page(s) 1029–1040

    Abstract: Background: Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS: Patients and methods: Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana- ... ...

    Abstract Background: Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRAS
    Patients and methods: Clinicopathologic and genomic information were collected from patients with NSCLCs harboring a KRAS mutation at the Dana-Farber Cancer Institute (DFCI), Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, and Imperial College of London. Multiplexed immunofluorescence for CK7, programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), Foxp3, and CD8 was carried out on a subset of samples with available tissue at the DFCI. Clinical outcomes to PD-(L)1 inhibition ± chemotherapy were analyzed according to KRAS mutation subtype.
    Results: Of 2327 patients with KRAS-mutated (KRAS
    Conclusions: KRAS
    MeSH term(s) B7-H1 Antigen ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/pathology ; Forkhead Transcription Factors ; Genomics ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/pathology ; Mutation ; Programmed Cell Death 1 Receptor ; Proto-Oncogene Proteins p21(ras)/genetics
    Chemical Substances B7-H1 Antigen ; Forkhead Transcription Factors ; KRAS protein, human ; Programmed Cell Death 1 Receptor ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language English
    Publishing date 2022-07-22
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2022.07.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.

    Cortellini, A / Ricciuti, B / Facchinetti, F / Alessi, J V M / Venkatraman, D / Dall'Olio, F G / Cravero, P / Vaz, V R / Ottaviani, D / Majem, M / Piedra, A / Sullivan, I / Lee, K A / Lamberti, G / Hussain, N / Clark, J / Bolina, A / Barba, A / Benitez, J C /
    Gorría, T / Mezquita, L / Hoton, D / Aboubakar Nana, F / Besse, B / Awad, M M / Pinato, D J

    Annals of oncology : official journal of the European Society for Medical Oncology

    2021  Volume 32, Issue 11, Page(s) 1391–1399

    Abstract: Background: Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut dysbiosis. Whether ATB also affects outcomes to chemo-immunotherapy combinations is ... ...

    Abstract Background: Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut dysbiosis. Whether ATB also affects outcomes to chemo-immunotherapy combinations is still unknown.
    Patients and methods: In this international multicentre study, we evaluated the association between pATB, concurrent ATB (cATB) and overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) in patients with non-small-cell lung cancer (NSCLC) treated with first-line chemo-immunotherapy at eight referral institutions.
    Results: Among 302 patients with stage IV NSCLC, 216 (71.5%) and 61 (20.2%) patients were former and current smokers, respectively. Programmed death-ligand 1 tumour expression in assessable patients (274, 90.7%) was ≥50% in 76 (25.2%), 1%-49% in 84 (27.9%) and <1% in 113 (37.5%). Multivariable analysis showed pATB-exposed patients to have similar OS {hazard ratio (HR) = 1.42 [95% confidence interval (CI): 0.91-2.22]; P = 0.1207} and PFS [HR = 1.12 (95% CI: 0.76-1.63); P = 0.5552], compared to unexposed patients, regardless of performance status. Similarly, no difference with respect to ORR was found across pATB exposure groups (42.6% versus 57.4%, P = 0.1794). No differential effect was found depending on pATB exposure duration (≥7 versus <7 days) and route of administration (intravenous versus oral). Similarly, cATB was not associated with OS [HR = 1.29 (95% CI: 0.91-1.84); P = 0.149] and PFS [HR = 1.20 (95% CI: 0.89-1.63); P = 0.222] when evaluated as time-varying covariate in multivariable analysis.
    Conclusions: In contrast to what has been reported in patients receiving single-agent ICIs, pATB does not impair clinical outcomes to first-line chemo-immunotherapy of patients with NSCLC. pATB status should integrate currently available clinico-pathologic factors for guiding first-line treatment decisions, whilst there should be no concern in offering cATB during chemo-immunotherapy when needed.
    MeSH term(s) Anti-Bacterial Agents/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Immunotherapy ; Lung Neoplasms/drug therapy ; Treatment Outcome
    Chemical Substances Anti-Bacterial Agents
    Language English
    Publishing date 2021-08-13
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1016/j.annonc.2021.08.1744
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2862: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top